NewsMunchies

JULY 10, 2023

AI tools are gaining popularity in biomedical research because while it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, using AI could vastly accelerate the drug-development process. AI automation opens up the possibility of faster, cheaper pharmaceuticals.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

APRIL 28, 2021

Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. Nasdaq:… Read More.

Pharmaceutical 98

Pharmaceutical Data Medicine Treatment 98

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

APRIL 26, 2021

TEL AVIV, Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. OTCQB: CNBX), a global leader in… Read More.

Pharmaceutical 59

Pharmaceutical Treatment Programs Cannabis 59

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Kind Meds (Cannabis Education Blog)

SEPTEMBER 1, 2020

One of the biggest areas of contention in the public debate about cannabis legalization is the viability of medicinal cannabis as a treatment for many mental health disorders, such as anxiety, depression, bipolar disorder, schizophrenia, and others. Cannabis Is a Unique Substance and Treatment Method. CBD for Mental Health Treatment.

Treatment 122

Treatment Research and Development CBD THC 122

Cannabis Law Report

JULY 1, 2021

As Curaleaf International ‘s subsidiary Adven GmbH seeks to advance its medical cannabis products in Germany, it has teamed up with an Italian pharmaceutical company, Zambon Spa , with whom it will provide medical cannabis treatments for patients, with an initial focus on neurological therapies.

Treatment 93

Treatment Pharmaceutical Therapy Oil 93

Project CBD

OCTOBER 26, 2023

United Kingdom-based GW Pharmaceuticals has produced the world’s first approved cannabis-based medicines for the UK, US, and European markets, Sativex® and Epidiolex®. GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising. Note: In May 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals.]

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Veriheal

AUGUST 31, 2020

Most of the conventional methods for treating migraines involve pharmaceutical medication, which has been known to be accompanied by unwanted side effects, especially from opioid based medication. The post New Research Shows Promising Treatment Results for Migraine Sufferers appeared first on Cannabis Central.

Treatment 98

Treatment Consumption Indica Hybrid 98

FloridaMarijuana.net

JUNE 27, 2018

Psychiatrists readily prescribe pharmaceuticals over marijuana when a patient is diagnosed with clinical depression. The post Medical Marijuana: An Alternative Treatment for Depression? Antidepressants alter the balance of chemicals in the brain to relieve symptoms of depression. appeared first on.

Treatment 100

Treatment Marijuana Data Conditions 100

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Veriheal

SEPTEMBER 18, 2020

Conventional forms of treatment are often accompanied by adverse side effects but there is hope for effective treatment with fewer side effects. . million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

Cannabis Law Report

SEPTEMBER 28, 2021

Acupuncture is one of the safest alternative forms of treatment for chronic pain. Ideally, it should be used in combination with other therapies, such as herbal medicine and massage, and can be a great addition to other treatments. Radio Frequency Treatment. Acupuncture. First, you need to find a certified acupuncturist.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

Veriheal

AUGUST 12, 2021

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

The Joint Blog

JULY 13, 2023

Classified as a neurological disorder, typical treatments include neuropathic painkillers that come with unpleasant side effects. Finding a natural alternative to these strong pharmaceuticals- one that doesn’t come with such downsides- could improve the lives of many sufferers. appeared first on The Joint Blog.

Treatment 47

Treatment CBD Clinical Trials Stress Management 47

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Canna Care Docs

NOVEMBER 4, 2024

cannabis has been used medicinally as a treatment for pain and other ailments. Today, you can explore personalized treatment plans to aid your distinctive needs. Patients with these conditions frequently seek relief from a variety of traditional treatments. Medicine and orthopedic concept. Since 2727 B.C.

Chronic Pain 111

Chronic Pain Nerve Pain Treatment Cannabinoids 111

Veriheal

SEPTEMBER 23, 2021

Fortunately, one such man, Levi Barker, provided us with some much-needed insight into what the substance is, how it is used in treatment, and more. Many of us have more in our minds than we need… Veriheal: Can you walk us through a typical iboga treatment? One could even say that iboga provides holistic healing.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Puff Puff Post

DECEMBER 28, 2018

Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism. The Current Treatments for Autism. As it sits, only a few methods of treating autism are available.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JANUARY 12, 2021

IRISYS, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that it was awarded… Read More.

Treatment 59

Treatment Cannabinoids Pharmaceutical Law 59

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. CONVENTIONAL TREATMENT. One of the goals of treating epilepsy is to allow people to continue to live functional and fulfilling life’s epilepsy treatment. CANNABIS AS A POTENTIAL TREATMENT.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Cannabis Law Report

OCTOBER 29, 2021

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin. Mydecine’s AI-driven drug discovery program is part of a joint research venture between the Company and Applied Pharmaceutical Innovation (API) at the University of Alberta. October 27, 2021. DENVER, Oct. DENVER, Oct.

Pharmaceutical 52

Pharmaceutical Research and Development Data Safety 52

Project CBD

OCTOBER 10, 2019

Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma.

Cannabinoids 224

Cannabinoids Clinical Trials Research and Development Pharmaceutical 224

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. He was the London Stroke Clinical Director from 2010-2019 and the National Clinical Director for Stroke for NHS England from 2013-2019, where he oversaw dramatic improvements in the paradigm of NHS stroke treatment. Moreau CEO of Algernon Pharmaceuticals Inc. “We

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

AUGUST 12, 2022

– August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL. ”

Extraction 52

Extraction Pharmaceutical Patients THC 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

FEBRUARY 14, 2020

a Canadian biotech firm, is entering Phase II clinical trials for two experimental treatments. The other trial will test LSD microdosing as an ADHD treatment. Mind Medicine, Inc. , According to its website, one trial involves an ibogaine-derived drug for treating opioid addiction.

Microdosing 45

Microdosing Treatment Medicine Clinical Trials 45